title: Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials.
abstract: It is now World Health Organization (WHO) policy that drug concentrations on day 7 be measured as part of routine assessment in antimalarial drug efficacy trials. The rationale is that this single pharmacological measure serves as a simple and practical predictor of treatment outcome for antimalarial drugs with long half-lives. Herein we review theoretical data and field studies and conclude that the day 7 drug concentration (d7c) actually appears to be a poor predictor of therapeutic outcome. This poor predictive capability combined with the fact that many routine antimalarial trials will have few or no failures means that there appears to be little justification for this WHO recommendation. Pharmacological studies have a huge potential to improve antimalarial dosing, and we propose study designs that use more-focused, sophisticated, and cost-effective ways of generating these data than the mass collection of single d7c concentrations.
authors: Liverpool School of Tropical Medicine, Liverpool, United Kingdom kwinter@liverpool.ac.uk.
authors: Katherine
authors: K
authors: Kay
authors: Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
authors: Eva Maria
authors: EM
authors: Hodel
authors: Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
authors: Ian M
authors: IM
authors: Hastings
mesh_terms: D000962:Antimalarials / Q000493:pharmacokinetics* / Q000627:therapeutic use; D037621:Artemisinins / Q000493:pharmacokinetics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D011804:Quinolines / Q000493:pharmacokinetics / Q000627:therapeutic use; D010879:Piperazines
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D011804:Quinolines; C039060:artenimol; C034759:piperaquine; D010879:Piperazines